SolarWinds Integrates with VMware to Automate IP Address Management for Virtual Environments
SolarWinds IP Address Manager makes it easy to fully automate the provisioning of virtual resources with native VMware vRealize Orchestrator integration
AUSTIN, Texas, Dec. 06, 2017 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today announced SolarWinds® IP Address Manager (IPAM) 4.6, which now integrates with VMware® vRealize®Orchestrator (vRO). With this extended functionality, IT professionals using the new offering can further improve virtual machine availability and reliability, both on-premises and in the cloud, through automated provisioning of IP addresses and DNS record management.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/538bb18f-0be9-4cd1-9c06-31cd2313ca5a
IPAM 4.6 removes the need for manual processes associated with IP address management tasks in virtual environments. This, in turn, helps eliminate multiple handoffs between admin teams, which can be time-consuming and error-prone. With IPAM 4.6, these environments will be able to scale dynamically with compute, storage, and now network addresses provisioned automatically.
The latest generation of SolarWinds IPAM is an affordable and easy-to-use DHCP, DNS, and IP address management overlay solution that offers centralized management of Microsoft®, Cisco®, and ISC DHCP servers, as well as BIND and Microsoft DNS Servers. IPAM also offers powerful monitoring, alerting, and reporting capabilities, and can alert IT admins of serious problems, such as IP address conflicts or subnet capacity issues. Now including vRO integration, the tool will provide IT professionals with unified management and monitoring of both their cloud and on-premises IP address spaces.
IPAM 4.6 Integration with VMware vRealize Orchestrator Highlights:
Easy-to-install vRealize Orchestrator plug-in for complete integration with SolarWinds IPAM
vRO plug-in contains actions and workflows essential for IP address and DNS management
The offering enables customers to easily create vRealize Automation blueprints to simplify/automate the provisioning and deprovisioning of VMs
"In virtual environments, on-demand availability is critical, and IT professionals can't achieve necessary performance levels by handling tasks manually," said Christoph Pfister, executive vice president of products, SolarWinds. "Our integration with VMware will allow customers to automate lifecycle management of virtual machines to achieve the desired performance levels for hybrid IT environments."
DHCP Failover for Windows Server, Additional Polling Engine Support
IPAM 4.6 includes other new capabilities. It offers DHCP failover support for Windows Server® that simplifies the creation and monitoring of failover relationships. Also, the new release offers additional poller support for increased scalability and deployment options.
Finally, IPAM 4.6 seamlessly integrates with other powerful SolarWinds tools, such as Network Performance Monitor, User Device Tracker and Server & Application Monitor to offer IT professionals a complete IT management solution.
Pricing and Availability
SolarWinds IP Address Manager pricing starts at $1,995 USD*. For more information, including a downloadable, free 30-day evaluation, visit the SolarWinds website, or call 866.530.8100.
*Price as of December 6, 2017. Pricing may vary based upon the jurisdiction and applicable currency. Please contact a local SolarWinds sales representative to find pricing specific to your jurisdiction.
Connect with SolarWinds
SolarWinds provides powerful and affordable IT management software to customers worldwide, from small businesses to Fortune 500® enterprises, managed service providers (MSPs), government agencies, and educational institutions. We are committed to focusing exclusively on IT, MSP, and DevOps professionals, and strive to eliminate the complexity that our customers have been forced to accept from traditional enterprise software vendors. Regardless of where the IT asset or user sits, SolarWinds delivers products that are easy to find, buy, use, maintain, and scale while providing the power to address key areas of the infrastructure from on-premises to the cloud. This focus and commitment to excellence in end-to-end hybrid IT performance management has established SolarWinds as the worldwide leader in both network management software and MSP solutions, and is driving similar growth across the full spectrum of IT management software. Our solutions are rooted in our deep connection to our user base, which interacts in our THWACK online community to solve problems, share technology and best practices, and directly participate in our product development process. Learn more today at www.solarwinds.com.
The SolarWinds, SolarWinds & Design, Orion, and THWACK trademarks are the exclusive property of SolarWinds Worldwide, LLC or its affiliates, are registered with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries. All other SolarWinds trademarks, service marks, and logos may be common law marks or are registered or pending registration. All other trademarks mentioned herein are used for identification purposes only and are trademarks of (and may be registered trademarks of) their respective companies.
© 2017 SolarWinds Worldwide, LLC. All rights reserved.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SolarWinds Worldwide, LLC via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30 | Pressmeddelande
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma
Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15 | Pressmeddelande
BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05 | Pressmeddelande
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public
Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00 | Pressmeddelande
OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to
Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29 | Pressmeddelande
ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern
Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum